Findings
A universally applicable evidentiary standard for biomarker qualification is not feasible; the necessary level of evidence depends entirely on the specific Context of Use (COU). The framework emphasizes that the strength of evidence is evaluated based on the potential risk and benefit associated with the biomarker’s intended application in drug development. The relationship between a biomarker and clinical outcomes must be robustly demonstrated, but there are no fixed quantitative criteria for this association. The overall confidence in a biomarker is derived from a combination of analytical validation, clinical validation, and the strength of the biological rationale.

Recommendations
Sponsors should clearly define the specific COU for the biomarker early in the development process, as this will dictate the required evidentiary support. It is recommended that sponsors engage with the FDA throughout the biomarker development and validation process to ensure alignment on the evidentiary requirements. Submissions for biomarker qualification should include a comprehensive package of evidence detailing the analytical validation (how well the test measures the biomarker) and the clinical validation (how well the biomarker relates to a clinical endpoint). Sponsors should provide a strong biological rationale for the biomarker’s role in the disease process and its relevance to the proposed COU.

Regulatory Considerations
The FDA’s evidentiary framework is designed to be a flexible, risk-based approach to biomarker qualification. The qualification is specific to the COU for which it was evaluated and does not imply acceptance for other uses. The framework is intended to support the use of biomarkers as Drug Development Tools (DDTs), which can include uses for patient selection, as surrogate endpoints, or to demonstrate a drug’s mechanism of action. The level of regulatory scrutiny is proportional to the impact the biomarker will have on drug development and clinical decision-making. Qualified biomarkers can help to de-risk and streamline the drug development process.